Meta Platforms and BlackRock announced on July 28, 2026, a $14 billion, 1-gigawatt data center campus in El Paso, Texas, structured as a joint venture in which BlackRock-managed funds will hold an 80% ownership stake and Meta will retain 20%. To finance the project, BlackRock is raising $12.3 billion through an investment-grade bond sale, while Meta is set to receive a $1 billion distribution to align ownership interests. The campus, which has been under construction for more than six months, is designed to support Meta's expanding AI compute requirements.
Verified by 1 source
Newsmax Inc. announced an AI content licensing partnership with Meta Platforms on July 28, 2026, granting Meta access to Newsmax's current and archived digital news content for use across Facebook, Instagram, and WhatsApp. The agreement is designed to improve the accuracy and balance of Meta's AI-powered queries, search, and discovery tools by incorporating licensed journalism. For Newsmax — a company with $195.6 million in annual revenue and 500 employees — the deal represents a new revenue stream from its existing content library.
Verified by 1 source
AT&T and D-Wave Quantum announced on July 27, 2026, an expansion of their collaboration applying annealing quantum computing to network operations optimization, including field technician dispatch and outage response. Early tests reduced computation time from approximately one hour to less than 15 seconds — a 240X acceleration. The partnership targets use cases spanning outage detection, technician routing, network build planning, and traffic management across AT&T's network infrastructure.
Verified by 1 source
A seven-day analysis of 1,308 SEC filings and 1,212 ArXiv papers reveals a parallel acceleration in AI-driven drug discovery and clinical gene therapy, with 694 gene therapy trials at Phase 3 or Phase 4 and 178 AI drug discovery trials currently active. The ArXiv corpus includes 54 large language model papers and 30 reasoning papers with documented medical scoring applications, which may indicate that the computational infrastructure for precision medicine is maturing alongside the clinical pipeline. Companies such as Beam Therapeutics (BEAM), Vertex Pharmaceuticals (VRTX), and Intellia Therapeutics (NTLA) operate pipelines directly positioned at this convergence point, spanning base editing, CRISPR/Cas9 in vivo therapy, and small-molecule modulation of genetic disease.
Verified by 1 source